STUDY TYPE: Prognosis (inception cohort). LEVEL OF EVIDENCE: 1b. OBJECTIVE: To evaluate the relationship between testosterone levels and the development of high-risk prostate cancer, by prospectively examining serum androgen concentrations in a well-studied cohort, as the role of testosterone in prostate cancer progression is debated. PATIENTS AND METHODS: The study comprised 781 men in the Baltimore Longitudinal Study of Aging who had sex steroid measurements before a diagnosis of prostate cancer, or at their last visit for those without cancer (no cancer, 636; cancer, not high risk, 109; cancer, high risk, 36). High-risk cancer was defined as death from prostate cancer, a prostate specific antigen (PSA) level of > or =20 ng/mL at diagnosis, or a Gleason score of > or =8. The hazard ratio (HR) of high-risk disease was determined using a Cox proportional hazards regression model with simple updating, and risk rates were stratified by age and tercile for androgens of interest based on the proportional hazards analyses. RESULTS: The likelihood of high-risk prostate cancer doubled per unit (0.1) increase in the free testosterone index (FTI) for patients aged >65 years (HR 2.07, 95% confidence interval, CI, 1.01-4.23; P = 0.047); the likelihood for men aged < or =65 years was inversely related to the FTI (HR 0.96, 95% CI 0.35-2.6; P = 0.9). The risk rate per person-years increased from lowest to highest tercile of FTI for the oldest men (age >70 years) but this trend was not apparent among younger men. CONCLUSION: Higher levels of serum free testosterone are associated with an increased risk of aggressive prostate cancer among older men. These data highlight the importance of prospective trials to insure the safety of testosterone-replacement therapy.
STUDY TYPE: Prognosis (inception cohort). LEVEL OF EVIDENCE: 1b. OBJECTIVE: To evaluate the relationship between testosterone levels and the development of high-risk prostate cancer, by prospectively examining serum androgen concentrations in a well-studied cohort, as the role of testosterone in prostate cancer progression is debated. PATIENTS AND METHODS: The study comprised 781 men in the Baltimore Longitudinal Study of Aging who had sex steroid measurements before a diagnosis of prostate cancer, or at their last visit for those without cancer (no cancer, 636; cancer, not high risk, 109; cancer, high risk, 36). High-risk cancer was defined as death from prostate cancer, a prostate specific antigen (PSA) level of > or =20 ng/mL at diagnosis, or a Gleason score of > or =8. The hazard ratio (HR) of high-risk disease was determined using a Cox proportional hazards regression model with simple updating, and risk rates were stratified by age and tercile for androgens of interest based on the proportional hazards analyses. RESULTS: The likelihood of high-risk prostate cancer doubled per unit (0.1) increase in the free testosterone index (FTI) for patients aged >65 years (HR 2.07, 95% confidence interval, CI, 1.01-4.23; P = 0.047); the likelihood for men aged < or =65 years was inversely related to the FTI (HR 0.96, 95% CI 0.35-2.6; P = 0.9). The risk rate per person-years increased from lowest to highest tercile of FTI for the oldest men (age >70 years) but this trend was not apparent among younger men. CONCLUSION: Higher levels of serum free testosterone are associated with an increased risk of aggressive prostate cancer among older men. These data highlight the importance of prospective trials to insure the safety of testosterone-replacement therapy.
Authors: Jason C Massengill; Leon Sun; Judd W Moul; Hongyu Wu; David G McLeod; Christopher Amling; Raymond Lance; John Foley; Wade Sexton; Leo Kusuda; Andrew Chung; Douglas Soderdahl; Timothy Donahue Journal: J Urol Date: 2003-05 Impact factor: 7.450
Authors: Pekka Kunelius; Olavi Lukkarinen; Minna L Hannuksela; Outi Itkonen; Juha S Tapanainen Journal: J Clin Endocrinol Metab Date: 2002-04 Impact factor: 5.958
Authors: Ian M Thompson; Phyllis J Goodman; Catherine M Tangen; M Scott Lucia; Gary J Miller; Leslie G Ford; Michael M Lieber; R Duane Cespedes; James N Atkins; Scott M Lippman; Susie M Carlin; Anne Ryan; Connie M Szczepanek; John J Crowley; Charles A Coltman Journal: N Engl J Med Date: 2003-06-24 Impact factor: 91.245
Authors: Anthony V D'Amico; Judd W Moul; Peter R Carroll; Leon Sun; Deborah Lubeck; Ming-Hui Chen Journal: J Natl Cancer Inst Date: 2003-09-17 Impact factor: 13.506
Authors: Antonio B Porcaro; Nicolò De Luyk; Paolo Corsi; Marco Sebben; Alessandro Tafuri; Giovanni Cacciamani; Davide De Marchi; Irene Tamanini; Davide Inverardi; Matteo Brunelli; Maria A Cerruto; Gian L Salvagno; Gian C Guidi; Walter Artibani Journal: Curr Urol Date: 2017-05-30
Authors: Dordaneh Sugano; Abhinav Sidana; Amit L Jain; Brian Calio; Sonia Gaur; Mahir Maruf; Maria Merino; Peter Choyke; Baris Turkbey; Bradford J Wood; Peter A Pinto Journal: Int Urol Nephrol Date: 2019-12-05 Impact factor: 2.370
Authors: Cindy Ke Zhou; Alyson J Littman; Paul H Levine; Heather J Hoffman; Sean D Cleary; Emily White; Michael B Cook Journal: Prostate Date: 2014-12-09 Impact factor: 4.104
Authors: Cindy Ke Zhou; Frank Z Stanczyk; Muhannad Hafi; Carmela C Veneroso; Barlow Lynch; Roni T Falk; Shelley Niwa; Eric Emanuel; Yu-Tang Gao; George P Hemstreet; Ladan Zolfghari; Peter R Carroll; Michael J Manyak; Isabell A Sesterhenn; Paul H Levine; Ann W Hsing; Michael B Cook Journal: Prostate Date: 2017-10-02 Impact factor: 4.104